WBDR-header

WBDR 2022 Data Report published

The World Federation of Hemophilia (WFH) World Bleeding Disorders Registry (WBDR) 2022 Data Report has been published. This fifth edition of the report includes aggregated data on 11,374 people with hemophilia (PWH) from 115 hemophilia treatment centres in 44 countries.

Also available in: Français Español

The World Bleeding Disorders Registry (WBDR) remains the only global registry for PWH, and it continues to support research and advocacy initiatives globally. The standardized data collected has been used for evidence-based decision making, to help understand the nature of gaps in treatment, and to improve hemophilia care. This year, we continue to see discrepancies in diagnosis and treatment between regions and between economic categories. There is a large gap in the median age at diagnosis for severe patients in high income countries when compared to those in low-income countries. The WBDR data show that only 30% of adults and 32% of children with severe hemophilia received prophylaxis in 2022; these figures are even lower for those in low and lower-middle income countries. The data also show that 20% of adults with severe hemophilia report that their employment status is negatively affected as a result of their diagnosis. This real-world evidence can be used to inform hemophilia care and policy development for ensuring equitable Treatment for All.

The WBDR continues to expand, and, in 2022, the platform became available in French, Spanish and Russian to increase its usability globally. Last year also saw the launch of the myWBDR mobile application, which allows patients to monitor their care, by tracking their bleeds and treatments, as well as their quality of life and burden of disease through the Patient Reported Outcomes Burdens and Experiences (PROBE) questionnaire. The app can also be used by patients to share their records with their healthcare provider.

In 2023, the WBDR started collecting data on people with von Willebrand disease (VWD). With continued support from participating hemophilia treatment centres (HTCs), we hope to advance care in people not only with hemophilia but with VWD as well.

The WFH greatly appreciates the efforts of participating HTCs and PWH. To find out more about the World Bleeding Disorders Registry (WBDR), click here. To read the WBDR 2022 Data Report, click here.

The WBDR is supported by Sobi and Takeda our Visionary Partners and Grifols, F. Hoffman-La Roche, Pfizer and Sanofi our Collaborating Partners.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.